| 12.30 Data as of May 17 |  -0.24 / -1.91%Today’s Change | 9.86 Today|||52-Week Range 31.21 | -8.35% Year-to-Date |
| ARNA Sheds Light on Belviq Launch - Analyst Blog May 09 / Zacks.com | VIVUS Reports Wider Loss - Analyst Blog May 09 / Zacks.com |
| Previous close | 12.54 |
| Today’s open | 12.63 |
| Day’s range | 12.20 - 12.71 |
| Volume | 1,538,032 |
| Average volume (3 months) | 2,466,022 |
| Market cap | $1.2B |
| Dividend yield | -- |
| Earnings growth (last year) | -158.18% |
| Earnings growth (this year) | -26.86% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 655.59 |
| Price/Book | 5.55 |
| Today’s change | Today’s % change | |
|---|---|---|
| INFIInfinity Pharmaceuti... | +0.59 | +2.43% |
| IPXLImpax Laboratories I... | -0.22 | -1.18% |
| SRPTSarepta Therapeutics... | +1.40 | +3.94% |
| TSROTESARO Inc | +0.03 | +0.08% |
| Next reporting date | August 5, 2013 |
| EPS forecast (this quarter) | -$0.45 |
| Annual revenue (last year) | $2.0M |
| Annual profit (last year) | -$139.9M |
| Net profit margin | -6,944.98% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President & Director Peter Y. Tam, MBA |
Chief Executive Officer & Director Leland F. Wilson |
Corporate headquarters Mountain View, California |
.
